Introduction
Dendritic cells (DCs) are the professional antigenpresenting cells of the immune system. Their decisive role in inducing immunity formed the rationale for DC immunotherapy: DC loaded with tumor antigens are injected into cancer patients to stimulate T cells to eradicate tumors.
Aim
To improve immunotherapy against cancer, adequate tumor specific immune monitoring is essential. Here, we evaluate our monitoring tools to predict clinical outcome to DC-based vaccination in melanoma patients.
Patients and methods
In our ongoing trials, HLA-A2.1 positive stage III and IV melanoma patients are vaccinated with DC loaded with gp100 and tyrosinase and control antigen keyhole limpet hemocyanin (KLH). Routine monitoring consisted of KLH specific responses in peripheral blood and tumor specific response in blood and cultures from DTH site biopsies.
Results
Upon vaccination, almost all patients showed proliferative and humoral responses to KLH. Tumor specific CD8 + T cells are rarely detected in peripheral blood and coincided with the presence of tumor specific CD8+ T cells in DTH site cultures [1] . We show the strong predictive value of presence of functional tumor specific CD8+ T cells in DIL cultures for PFS and overall survival (OS) in metastatic melanoma patients, and show similar significant correlation for PFS in stage III melanoma patients.
Conclusion
Monitoring of KLH specific proliferative responses or tumor-specific T cells in peripheral blood was not predictive for improved clinical outcome. Our findings show that the presence of functional tumor-specific T cells in DTH site biopsies predict clinical outcome. Submit your next manuscript to BioMed Central and take full advantage of: 
